BRCA1 and cancer: In hereditary BRCA1/2 mutation carriers, Castro found that the risk of stage T3/T4 cancer, nodal involvement, a Gleason score of 8 or higher, and metastases at the time of initial diagnosis was increased and that the survival time was also decreased (Castro et al., 2013).